tropicamide and Sialorrhea studies

Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.

Research Excerpts

Excerpt	Relevance	Reference
"This proof-of-concept, pilot study aimed to explore the safety and anti-sialorrhea efficacy of single doses of intra-oral slow dissolving thin films containing tropicamide (NH004) or placebo."	9.15	A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. ( Carrosella, A; Gamzu, E; Lloret, SP; Merello, M; Nano, G, 2011)
"This proof-of-concept, pilot study aimed to explore the safety and anti-sialorrhea efficacy of single doses of intra-oral slow dissolving thin films containing tropicamide (NH004) or placebo."	5.15	A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. ( Carrosella, A; Gamzu, E; Lloret, SP; Merello, M; Nano, G, 2011)
" The advantages of NH004 include local bioavailability with low systemic exposure, rapid onset of action and, importantly, convenience of use for patients."	2.52	Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease. ( Farber, NM; Gamzu, ER; Perez-Lloret, S, 2015)

Research

Studies (2)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Percentage Change in Saliva Volume

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Farber, NM	1
Perez-Lloret, S	1
Gamzu, ER	1
Lloret, SP	1
Nano, G	1
Carrosella, A	1
Gamzu, E	1
Merello, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients[NCT00761137]	Phase 2	19 participants (Actual)	Interventional	2008-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Saliva volume was measured at baseline and 75 minutes after treatment administration. Volumes were measured by using cotton rolls placed near each Stenton duct and below the tongue for 5 minutes; cotton rolls were centrifuged and the volume of saliva determined. (NCT00761137)
Timeframe: Before and 75 minutes after treatment administration

Sialorrhea Visual Analogue Scale (VAS)

Intervention	percentage change of saliva volume (Median)
Tropicamide - Placebo	-5
Tropicamide - 0.3 mg	-27
Tropicamide - 1 mg	-33
Tropicamide 3 mg	-20

Saliva buccal assessment was evaluated by an VAS scale before, and 15, 30, 45, 60, 90, and 120 min after treatment administration. Subjects were asked to rate how much saliva they perceived in their buccal cavity on an unmarked 0 to 10 cm line, higher scores meaning greater perceived buccal saliva levels. (NCT00761137)
Timeframe: Before and 120 min after treatment administration

Intervention	cm on VAS (Mean)
Tropicamide - Placebo	-0.55
Tropicamide - 0.3 mg	-1.08
Tropicamide - 1 mg	-1.53
Tropicamide 3 mg	-0.81

tropicamide and Sialorrhea